MedDataX Logo

Protocols for Prevention of PPH During CS in High Risk Group

NCT ID: NCT05099575

Last Updated: 2021-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

448 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-30

Study Completion Date

2022-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atonic PPH

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women who receive oxytocin

Syntocinon, papal, misotac

Intervention Type DRUG

Using different drugs to prevent atonic PPH during CD in high risk group

Pregnant Women who receive carbetocin

Syntocinon, papal, misotac

Intervention Type DRUG

Using different drugs to prevent atonic PPH during CD in high risk group

Pregnant women who receive misoprostol

Syntocinon, papal, misotac

Intervention Type DRUG

Using different drugs to prevent atonic PPH during CD in high risk group

Pregnant women who receive ergometrine

Syntocinon, papal, misotac

Intervention Type DRUG

Using different drugs to prevent atonic PPH during CD in high risk group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Syntocinon, papal, misotac

Using different drugs to prevent atonic PPH during CD in high risk group

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Pregnant full term\>37 w 2. Maternal age 19- 40 3.physical state 1\&2 4.patient willing to enter the study

Exclusion Criteria

* 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug
Minimum Eligible Age

19 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Randa Wanees Ahmed

Randa Wanees Ahmed

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Atonic PPH in high risk group

Identifier Type: -

Identifier Source: org_study_id